Keywords hepatoblastoma - imaging guidelines - neuroblastoma - pediatric oncology - pediatric
solid tumors - Wilm's tumor
Childhood cancer accounts for nearly 1% of all cancers diagnosed worldwide across
all age groups.[1 ]
[2 ] Great improvement has been made in the last few decades in the treatment of childhood
cancers, achieving successful treatment in up to 80% of cases.[1 ] This dramatic success is a result of decades of collaborative effort by various
study groups across the globe. Collaborative consensus guidelines have been developed
by these groups for imaging and management of pediatric tumors.
This article aims to provide imaging guidelines for the common pediatric extracranial
solid tumors based on the recommendations of various pediatric groups across the world
and treatment protocols followed in India.
Clinical Presentation
Pediatric tumors present with nonspecific symptoms and requires high index of suspicion
to investigate for the possibility of cancer. Pediatric abdominal malignancies present
most commonly as abdominal distension or a palpable abdominal mass. It may be an incidentally
detected mass or present with abdominal pain, hematuria, features of bowel or bladder
obstruction, or may present with constitutional symptoms such as fatigue, loss of
appetite or fever. Renal and suprarenal tumors may present with hypertension or paraneoplastic
symptoms such as opsoclonus-myoclonus.[3 ]
[4 ] Occasionally, they may present with precocious puberty/virilization, more so in
adreno-cortical carcinomas, and rarely in hepatoblastoma and germ cell tumors.[5 ]
Soft tissue tumors may present with swelling or bone pain. Spinal extension of the
tumor like in neuroblastoma or germ cell tumors may cause focal neurological deficits
or bowel/bladder related symptoms.
Imaging Guidelines for Pediatric Abdominal Masses
Imaging Guidelines for Pediatric Abdominal Masses
Ultrasound
Ultrasound is the ideal screening tool in cases of suspected abdominal mass in children
as there is no ionizing radiation or sedation involved.
Role of ultrasound is to confirm the presence of mass and determine its organ of origin.
Further investigations would be based on the ultrasound findings ([Fig. 1 ]).
Fig. 1 Diagnostic pathways based on ultrasound findings.
Relook ultrasound after cross sectional study, along with Doppler might be useful
to evaluate subtle vascular invasion or thrombosis in cases of doubt, e.g., tumor
thrombus in hepatoblastoma or Wilm's tumor. It is a problem solving tool in cases
of complex findings on cross-sectional imaging, e.g., suspected focal lesions in hepatoblastomas
and lesions in contralateral kidney in cases of Wilm's tumor. In cases of suspected
tumor rupture, ultrasound has a role in evaluating the tumor margin integrity and
detecting echoes in the abdominal free fluid. USG-guided biopsy of solid pediatric
tumors is a widely acceptable technique and again avoids unnecessary radiation (compared
with CT scan).
Magnetic Resonance Imaging
MRI is the modality of choice for pediatric abdominal masses.[6 ] It provides better soft tissue contrast and does not expose to any ionizing radiation.
However, sedation risk should be considered against radiation risk and CT scan can
be performed for cases with contraindication to MRI or difficult anesthesia or no
availability.[7 ] MRI field strength of 1.5 to 3 T and acquisition with the smallest suitable coil
(e.g., head coil or flexible phased-array body coil) is recommended with breath holding
and gated sequences. Study may be performed under sedation or general anesthesia if
needed, depending on the age and weight of child.
CT Scan
A contrast-enhanced CT scan for hepatic or renal masses is the alternative imaging
modality to MRI as per institute preference, or if MRI is contraindicated or anesthesia
is not available. Care should be taken to use the lowest possible radiation dose with
adequate image quality. Single-phase imaging is recommended if sufficient to provide
necessary information. Just a non-contrast CT scan is usually avoided. The imaging
protocols are further tailored as per the organ of origin of the mass and will be
discussed subsequently.
A CT chest is a mandatory diagnostic procedure for all patients of liver and renal
masses and protocol is described in the respective sections.
Pediatric Liver Tumors
Pediatric liver tumors are rare and ∼two-thirds of them are malignant, hepatoblastoma
being the most common, (∼37%) followed by hepatocellular carcinoma (HCC; 21%), and
sarcoma (8%).[8 ] Benign tumors such as hemangioma, hemangioendothelioma, focal nodular hyperplasia,
and mesenchymal hamartomas form the rest of the spectrum.
Risk Factors, Etiopathogenesis, and Clinical Presentation
Risk Factors, Etiopathogenesis, and Clinical Presentation
Hepatoblastoma are mostly sporadic, but may be associated with genetic abnormalities
and familial cancer syndromes, such as the Beckwith–Wiedemann syndrome and familial
adenomatous polyposis.[9 ] Premature birth and very low birth weight are known to be associated with increased
incidence of hepatoblastoma.[10 ]
The most common presenting symptom is abdominal distension or a palpable abdominal
mass. It may be associated with non-specific symptoms such as abdominal discomfort,
fatigue, and loss of appetite, and the child may appear pale due to anemia, especially
in HCC and liver sarcomas
Imaging Guidelines for Pediatric Liver Lesions
Imaging Guidelines for Pediatric Liver Lesions
Ultrasonography
USG is the ideal screening modality for suspected liver mass/abdominal lump.[6 ]
[11 ]
Contrast-enhanced USG can be performed for the initial assessment of lesion to help
classify as benign or malignant. USG may be useful to evaluate hepatic veins, IVC,
portal vein, and focal liver lesions and for suspected cases of tumor rupture.
Magnetic Resonance Imaging
Both MRI and CECT are the modality of choice for pediatric liver masses such as hepatoblastoma
and HCC.
Respiratory gated sequences should be used. Unlike adults, breath holding is usually
not possible for hepatoblastoma evaluation as these scans are generally performed
under sedation or GA. The recommended MRI sequences are presented in [Table 1 ].
Table 1
Imaging recommendations for pediatric abdominal tumors
MRI sequence
Plane
Thickness
Sequence coverage
T2 STIR
Coronal
5 mm
Above diaphragm to below iliac crests
T1 TSE FS
Coronal
2 mm
Above diaphragm to below iliac crests
T1 TSE FS
Axial
2 mm
Above diaphragm to below iliac crests
T2W volume sequence (SPACE/VISTA)
Coronal
0.9 mm–1.1 mm
Above diaphragm to below iliac crests
T2W STIR
Axial
5 mm
To include area of interest
T1W IP and OP
Axial
5 mm
To include area of interest
DWI/ADC (b = 0,100,500,1000)
Axial
6 mm
To include area of interest
Post-contrast
T1W FS immediate (VIBE)
Axial
2 mm
Above diaphragm to below iliac crests
T1W FS 30 s arterial (VIBE)
Axial
2 mm
Above diaphragm to below iliac crests
T1W FS 60 s venous (VIBE)
Axial
2 mm
Above diaphragm to below iliac crests
T1W FS 2 min (VIBE)
Axial
2 mm
Above diaphragm to below iliac crests
T1W FS 5 min (VIBE)
Axial
2 mm
Above diaphragm to below iliac crests
T1W FS 10 min (VIBE)
Axial
2 mm
Above diaphragm to below iliac crests
T1W TSE FS
Axial
5 mm
Above diaphragm to below iliac crests
T1W FS 20 min (VIBE)
Coronal
2 mm
Above diaphragm to below iliac crests
T1W FS 25 min (vibe)
Axial
2 mm
Above diaphragm to below iliac crests
Note: Please note the number of slices, field of view, and TR/TE for the sequences
will be variable depending on if it is a young child/old child
MRI with contrast is also the modality of choice for post chemotherapy response evaluation,
detection of metastatic liver lesions in non-hepatic primary tumor and in the follow
up of patient with resected tumor.
CT Scan
Contrast-enhanced CT scan is the alternative imaging modality of choice as per the
institute preference, or if there is contraindication for MRI, anesthesia is not available
for MRI or separate anesthesia is needed for CT chest and MRI.
A single-sequence baseline CECT abdomen can be performed that includes both arterial
and venous phases ([Table 2 ]). Alternatively, dual-phase CT with late arterial phase for abdomen and portal-venous
phase for the abdomen and pelvis should be performed in the evaluation of suspected
hepatoblastoma. A triphasic CT with an additional delayed phase can be performed for
suspected HCC. A CT scan of the chest is recommended in all patients of hepatoblastoma
for the evaluation of lung metastasis.
Table 2
Single phase CECT abdomen protocol for pediatric abdominal tumors
Imaging recommendation
Protocol
Contrast dose
Reconstructions
CT Abdomen ± Chest
-To include lung apices to lesser trochanter
-Inject two-thirds of contrast bolus @ 0.5 mL per sec and one-third @ 1 mL per second
-Scan after 10 seconds post injection
Slice thickness – 0.6 mm
Increment – 0.6 mm
Pitch – 0
2 mL/kg (dose recommendations for Iohexol 300)*
Lung window:
- Axial 1 mm
- Cor 3 mm
- -Sag 3 mm
Soft tissue window (chest and abdomen):
- Axial 1 mm
- Cor 3 mm
- Sag 3 mm
Bone window:
- Cor 2 mm
- Sag 2 mm
*Contrast type and dose used can be variable as per local department policies.
Intervention
Recommendations for biopsy: Serum α fetoprotein (AFP) level is the most important
clinical tumor marker for hepatoblastoma and is elevated in 90% of cases. Biopsy is
not mandatory in cases with elevated serum AFP levels, and when imaging features are
in favor of hepatoblastoma. In cases with uncertain diagnosis, low AFP levels or age
of the patient < 6 month or > 3 years, a biopsy can be performed after a multidisciplinary
discussion.
Reporting
The PRETEXT staging system should be used as a consensus classification for pre-treatment
extent of pediatric liver tumors. Each PRETEXT annotation factor should be evaluated
during reporting as the presence of any of the annotation factors upgrades the tumor
from standard risk to high risk and can change the chemotherapy regime. The imaging
reassessed after chemotherapy should be classified using the POST-TEXT staging system.[11 ] The future liver remnant (FLR) should be considered before surgery to avoid decompensation
in the post-operative period.
Management
Hepatoblastoma: The tumor should be classified as high risk or standard risk based
on the risk stratification system followed by the institution. Upfront surgery can
be performed in cases such as PRETEXT 1 and small PRETEXT 2 tumors. Neoadjuvant chemotherapy
is needed in cases with high tumor burden followed by complete surgical resection.
Liver transplant is indicated in the PRETEXT IV multifocal/solitary POST-TEXT IV/portal
vein involvement/all three hepatic veins involved/central hepatoblastomas with insufficient
tumor regression/unsuccessful resection/recurrence cases.[12 ]
HCC: Only 20% of pediatric HCC are upfront resectable. Patients with upfront unresectable
HCC are treated with neoadjuvant chemotherapy on the same lines as hepatoblastoma
and reassessed for surgery.
Pediatric Renal Tumors
Introduction and Epidemiology
Wilm's tumor is by far the most common renal tumor of childhood, comprising up to
90% of all renal masses in children.[13 ] Children between the age of 1 and 5 years are the most commonly affected, and the
peak incidence is at 3 years. Wilm's tumor is extremely uncommon after the age of
15 years. Bilateral Wilm's tumor are seen in up to 5 to 8% of patients.[14 ]
Risk Factors, Etiopathogenesis, and Clinical Presentation
Majority of the Wilms tumor are sporadic, but 10% may be associated with genetic abnormalities
such as aniridia, genitourinary defects, hemihypertrophy or syndromes such as WAGR
(Wilm's tumor, aniridia, genito-urinary abnormalities and mental retardation/intellectual
disability) syndrome, Denys–Drash syndrome, and Beckwith-Wiedemann. Mutation of the
Wilms Tumor 1 gene (WT1 ), on the short arm of chromosome 11 (11p13) are associated with congenital anomalies.[15 ]
Imaging Guidelines for Pediatric Renal Lesion
USG is usually the first imaging modality that confirms the renal origin of the suspected
abdominal mass. Cross-sectional imaging (CT/MRI) is needed for further characterization
and determination of the extent as well as for local staging ([Supplementary Table S1 ], available online only). Evaluating the other kidney is of paramount importance
as it upstages the disease and also rules out congenital anomalies that affect the
management. USG Doppler in addition to cross-sectional imaging may help in the evaluation
of IVC and renal vein thrombus.
Cross-sectional study for further evaluation ([Supplementary Table S1 ], available online only). As per the institute, preference could be
MRI of the abdomen with CT scan of the chest
OR
Contrast-enhanced CT scan of the chest, abdomen, and pelvis
MRI Abdomen
Contrast MRI of the abdomen is preferred on a MRI field strength of 1.5 or 3 Tesla.
Recommended MRI sequences (check the general abdominal MRI protocol) are large FOV
STIR coronal and axial sequences for an overview of the abdomen. T2 non-fat saturated
high-resolution sequence for both the kidneys, the name for it differs between different
vendors (SPACE/VISTA). Pre-contrast axial T1W sequence. Diffusion-weighted images
should be included with at least three b-values (b = 0, b = 500, and b = 1000). Post
contrast sequences should include multiple contrast phases to cover arterial, venous,
and delayed phases. MRI is the modality of choice to identify nephrogenic rests, which
are better appreciated on post contrast images in the background of enhancing parenchyma
and also seen well on DWI as areas of restricted diffusion.
CT Scan
CT scan of the abdomen and pelvis is still the preferred modality in many institutes.
A single post contrast acquisition in the portal-venous phase should be performed
for tumor assessment. CT scan of the chest is also mandatory. A plain CT chest is
sufficient if MRI of the abdomen is performed; however, contrast CT chest is recommended
if an IVC tumor thrombus is suspected. However, if contrast-enhanced CT scan of the
abdomen and pelvis is the cross-sectional diagnostic procedure performed, a contrast-enhanced
CT chest should be performed in the same setting.
Management of Pediatric Renal Tumors
The management of pediatric malignant renal masses and timing of surgery varies in
different groups. In India, the renal tumor size is usually large at presentation.
A customized approach is recommended based on the baseline imaging considering the
risk of rupture or incomplete resection if upfront surgery is performed as described
in [Fig. 2 ].[16 ] Biopsy is recommended before starting chemotherapy if upfront surgery is not possible.
Fig. 2 Guidelines for the imaging and management of pediatric renal tumors.
Radical nephroureterectomy and lymph node sampling is the surgical procedure of choice[17 ] Clearance of the thrombus, if present, is performed and either cavotomy or partial
cavectomy may be required depending on the extent of tumor thrombus.[18 ] As Wilm's tumor is highly chemo-sensitive, post-operative chemotherapy is recommended
for every patient, and the dosage regimen is decided based on the histology and tumor
stage ([Supplementary Table S2 ], available online only). Except for stage 1 and 2 tumors with favorable histology,
post-operative radiotherapy is indicated for primary tumor bed and metastatic disease.[16 ]
[19 ]
Upfront surgery is contraindicated in bilateral renal disease and in cases with solitary
or horseshoe kidney.[16 ]
[20 ] For patients with bilateral Wilm's tumors, neoadjuvant chemotherapy is initiated,
followed by delayed surgery in the form of bilateral partial nephrectomy or total
nephrectomy on the worse side and partial nephrectomy on the opposite side. Patients
with tumor spillage/rupture, or regional lymph node metastasis are upstaged to stage
III, and should receive abdominal radiotherapy and appropriate chemotherapy.[19 ]
[21 ]
Follow-up of patients: Done with USG of the abdomen and pelvis along with chest radiograph ([Supplementary Table S2 ], available online only).[11 ]
Extracranial Germ Cell Tumors (Pediatric)
Extracranial Germ Cell Tumors (Pediatric)
Malignant germ cell tumors (GCT) account for 3% of pediatric cancer with bimodal age
distribution.[22 ]
[23 ] Sites are divided as intracranial or extracranial, the later as gonadal and extragonadal.
The extragonadal sites comprise sacrococcygeal, mediastinal, retroperitoneal, and
other para-axial locations. Histologically, the germ cell tumors are classified as
germinoma (dysgerminoma and seminoma), and non-germinomatous tumors such as endodermal
sinus (yolk sac tumor), embryonal carcinoma and choriocarcinoma, or mixed type where
more than one histology co-exist.
Risk Factors, Etiopathogenesis, and Clinical Presentation
Cryptorchidism and gonadal dysgenesis are associated with an increased risk of the
development of gonadal GCT.[24 ] Some GCTs are more frequently seen with sex-linked chromosomal disorders; mediastinal
GCT in Klinefelter's syndrome, germinomas in Turner's syndrome, and Swyer's syndrome.
Clinical features are variable and the presentation depends on the site of the extracranial
GCT.[24 ] Sacrococcygeal GCT usually present as an external palpable mass in perinatal period.
Testicular GCT may present as a painless swelling. Ovarian and abdominal or retroperitoneal
GCT present with gradual abdominal distension and discomfort. Rarely ovarian GCT may
present as acute abdomen due to torsion, rupture, or intralesional hemorrhage. Mediastinal
GCT causes symptoms due to mass effects such as airway compression, superior vena
cava obstruction, or heart failure.
Diagnostic Work-up of Germ Cell Tumors
Tumor markers important for the diagnosis of GCT are α fetoprotein (aFP) secreted
by yolk sac tumors and β human chorionic gonadotropin (b-hCG) secreted by choriocarcinoma.
LDH is a non-specific marker of tumor burden.[25 ] The imaging recommended at baseline and for follow-up is summarized in [Supplementary Table S3 ], available online only.
USG
USG is the modality of choice for the evaluation of suspected testicular pathology.
Trans-scrotal USG using a linear high-frequency probe has more than 90% sensitivity
and specificity in detection of testicular malignancies. In adjunct to gray scale
and color Doppler, elastography provides an added value.[26 ] USG is usually the initial imaging modality for abdominal and pelvic GCT.
Cross-sectional Imaging
Primary site evaluation can be performed with CT scan or MRI based on the site involved
and local institutional policy.
CT Scan
Contrast-enhanced single venous phase CT scan of the chest, abdomen, and pelvis is
suggested for initial staging of abdominal GCT.[25 ]
[27 ] It is a sensitive modality for assessing retroperitoneal nodes. Noncontrast CT scan
of the chest is recommended for the evaluation of lung metastasis
MRI Scan
MRI is used as an adjunct tool to USG, in cases of testicular mass with diagnostic
dilemma on ultrasound. MRI abdomen and pelvis may be used instead of CT for both baseline
evaluation and post treatment reassessment. MRI may particularly be used for initial
workup in patients with deranged renal profile or in cases with suspicious intraspinal
extension.
Contrast CT or MRI of the head should be performed if brain metastasis is suspected
and in all patients with metastatic choriocarcinoma.
Recommendations for Biopsy: Biopsy is performed if AFP is not elevated and neoadjuvant
chemotherapy is planned. Biopsy is not recommended for upfront resection or in testicular
tumors where high orchidectomy is planned. Biopsy is performed when tumor markers
are normal and/or there is a clinicoradiological mismatch.[27 ]
Management
A multi-modality customized strategy is needed for the treatment of GCT depending
on the site, stage, and tumor biology. The COG staging for testicular, ovarian, and
extragonadal germ cell tumors is recommended. GCTs are stratified into low-, intermediate-,
and high-risk categories.
Surgery is the mainstay of management and first treatment option if feasible. A biopsy
with neoadjuvant chemotherapy is otherwise recommended.
Neuroblastoma
Neuroblastoma (NB) is a neuroectodermal tumor arising from the sympathetic ganglion
cells and is the commonest extracranial solid tumor in children.[28 ] This tumor commonly arises in the adrenal gland and can also occur at multiple locations
including the extraadrenal abdomen, thorax, neck, and pelvis along the course of sympathetic
nervous system.[29 ] Patients usually present with symptoms caused due to its mass effect on the surrounding
organs, mostly presenting as a large abdominal mass.
Imaging Guidelines and Principles of Management
Imaging Guidelines and Principles of Management
The treatment and outcome of NB are dependent on risk assessment and stage of the
disease. The international Neuroblastoma Risk Group (INRG) task force puts forth a
preoperative staging called International Neuroblastoma Risk Group Staging System
(INRGSS), which is dependent on cross-sectional imaging (CECT or MRI) of the tumor
site using Imaging defined risk factors (IDRF) ([Supplementary Tables S4 ] and [S5 ], available online only). A metastatic workup includes an iodine-labeled MIBG scan
(radionuclide 123/124 or 131 iodine is used; however, in India, only 131 iodine is
available) to look for sites of metastatic disease, especially bone lesions, a bone
marrow biopsy, and aspirate for marrow disease.[29 ]
[30 ] The IDRFs on cross-sectional imaging help categorize the patients into L1 (non-infiltrative/operable
tumor) or L2 (infiltrative or disease-encasing important structures) ([Supplementary Table S6 ], available online only).[29 ] Combining the outcome of these tests with other pathological and molecular criteria,
and age of the patient help make decisions for management plan.
Data are emerging for the potential role of FDG PET-CT in the evaluation of neuroblastoma.
In the Indian set-up, due to the unavailability of I-123 for MIBG scans, I-131 MIBG
is performed. For the MIBG non-avid NB lesions, PET-CT is preferred modality for metastatic
work-up. The utility of PET-CT for all NB patients work-up is debatable as there are
some studies that have shown higher sensitivity of PET-CT compared with I-123 MIBG
scans for stage 1 or 2 disease, but MIBG has performed better for higher stages of
NB.[31 ]
Patients are treated with surgery alone in L1, low-risk disease or initially with
chemotherapy followed by surgery, which could be a complete resection or an incomplete
resection in patients with intermediate risk disease (patients having an unfavorable
histology or infantile age group with metastasis receiving additional cycles of chemotherapy).
Patients with high-risk neuroblastoma undergo bone marrow transplant after initial
intensive chemotherapy and surgery followed by radiotherapy and administration of
differentiation agents and immunotherapy if available.
MRI/CT and MIBG scan along with bone marrow biopsy are done pre-surgically to look
for residual disease, as this may alter the management of the disease.
Rhabdomyosarcoma
Introduction
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma and accounts
for 3 to 5% of all pediatric malignancies. It is the third most common soft tissue
tumor in children after neuroblastoma and Wilm's tumor.[32 ] RMS in children has two main histological subtypes, embryonal and alveolar. Further
refinement of prognosis has occurred over the years with the incorporation of molecular
fusion status for PAX 3/7-FOXO1 with fusion-positive tumors faring worse than fusion-negative
ones. The embryonal type (nearly 75% of RMS cases), which is mostly fusion negative,
is more common in younger children (<10 years of age), has better prognosis, and occurs
in the head and neck region, followed by genitourinary tract and retroperitoneum.
The alveolar variant, which is usually fusion positive, is the more aggressive type
(∼16% of RMS cases) and commonly occurs in the trunk and extremities.
Risk Factors and Etiopathogenesis and Clinical Presentation
There are no clear risk factors for RMS. Higher risk of developing RMS has been shown
in children who have the following rare, inherited conditions: Li-Fraumeni syndrome,
Beckwith–Wiedemann syndrome, neurofibromatosis, DICER 1, cardio-facio-cutaneous syndrome,
Costello syndrome.[33 ]
There are no clear signs or symptoms for RMS and the presentation is largely dependent
on the location of the lesion. RMS is known to have metastasis at presentation in
15 to 20% of cases, and the common sites for metastasis are lungs, bone marrow, bones,
and distant lymph nodes.[34 ] Tumor biopsy is routinely performed as part of the main tumor work-up and at least
one bone marrow aspirate and trephine performed for evaluating bone marrow involvement.
The metastatic work-up includes lymph node biopsy, bilateral bone marrow aspirates,
and CSF examination when LN, bone marrow, or neurological metastasis is suspected.
The RMS cases are risk stratified into low-risk, intermediate-risk, high-risk or very
high-risk category based on age, tumor size, regional nodal status, tumor site, histology,
PAX-FOX01 status, and Intergroup Rhabdomyosarcoma Study (IRS) post-surgical stage.
Treatment for RMS cases is multimodality and in low/intermediate risk categories,
the approach is chemotherapy in combination with radiotherapy and/or surgery with
additional maintenance chemotherapy in high risk cases. Localized radiotherapy for
metastatic disease can be used. In spite of recent advancements, multicenter trials
and significantly improved treatment protocols, the 5-year overall survival for pediatric
RMS stands at 75% for cases with localized disease, dropping to just 30% for cases
with metastatic disease.[35 ]
[36 ]
Imaging Guidelines
Imaging the primary tumor should include loco-regional lymph node sites and also cover
the regional extent of the tumor including the neuro-vascular structures. Evaluation
for metastasis should include chest CT scan and bone scan or PET-CT for complete staging.
Complete imaging and staging should be performed before biopsy is performed. All the
imaging should be planned and reported by a pediatric radiologist with oncology experience
and a nuclear medicine physician for hybrid imaging. Imaging reports should clearly
describe the lesion location, size, lesion characteristics, extent and status of surrounding
structures including regional lymph nodes.
MRI
MRI is the imaging modality of choice for both initial imaging of the tumor and subsequent
follow-up examinations ([Table 3 ]). The MRI protocol should include DWI/ADC and post-contrast imaging. Lesions with
diffusion restriction and lower ADC values have shown to correlate with poor outcome
and higher incidence of recurrence.[37 ] Post-contrast tumor enhancement helps to map tumor response and also study neurovascular
spread (for head and neck RMS). The MRI field of view should include areas of loco-regional
lymph nodes.
Table 3
MRI imaging protocol recommendations for pediatric rhabdomyosarcoma
MRI sequence
Plane
Thickness
Sequence coverage
T2 STIR
Sag
5 mm
Pelvic lesion only (below liver to symphysis pubis)
T1 TSE
Axial
5 mm
Above diaphragm to below symphysis pubis
T1 TSE FS
Axial
2 mm
Above diaphragm to below symphysis pubis
T2W volume sequence (SPACE/VISTA)
Coronal
0.9 mm–1.1 mm
Above diaphragm to below symphysis pubis
T2W STIR
Axial
5 mm
To include area of interest
DWI/ADC (b = 0,100,500,1000)
Axial
6 mm
To include area of interest
Post-contrast
T1W FS (VIBE) 1
Axial
2 mm
Above diaphragm to below symphysis pubis
T1W FS (VIBE)
Coronal/Sag
2 mm
Above diaphragm to below symphysis pubis
T1W FS (VIBE) 2
Axial
2 mm
Above diaphragm to below symphysis pubis
Note: Please note, the number of slices, field of view and TR/TE for the sequences
will be variable depending on if it is a young child/old child.
CT Scan
Only in circumstances where MRI cannot be performed for the primary tumor site, a
contrast CT scan (ideally single phase) should be done ([Table 2 ]). A single-phase contrast CT scan is sufficient to evaluate both the soft tissue
and bones. Intravenous contrast medium should be given at a dose of 2 mL/kg patient
body weight followed by saline bolus, and images should be acquired at 65 to 70 seconds
post-injection. CT can be done in addition to MRI to evaluate for skull base involvement
or to look for bone erosions. Metastatic work-up should include a good inspiratory
phase chest CT scan with 1 mm thin lung window reconstructions (non-contrast scan
to be done when paired with PET-CT).
PET-CT/PET-MRI
A hybrid nuclear scan is mandatory for complete RMS staging before commencing treatment.
Smaller lesions, nodal metastasis, and bone metastasis are better seen on PET-CT/PET-MRI
compared with conventional scans. A modified Deauville score can be used to for visual
assessment of suspicious lymph nodes comparing the activity with background activity
in the adjacent normal tissue. Lymph nodes < 10 mm are considered non-pathological
and > 15 mm are pathological. Lymph nodes < 15 mm with FDG activity should be considered
suspicious. Although not validated, PERCIST (PET response criteria in solid tumors)
can be used for quantitative measurements using standardized uptake values (SUV).[38 ] In future, whole body MRI with DWI/ADC sequence can prove to be a promising alternative
to PET scans; however, it is still a subject of research and widespread adaptability
for pediatric MRI protocols.
Response Assessment
Timing
The current EBM guidelines[39 ] and the EpSSG protocols use multidrug chemotherapy. Induction chemotherapy is combined
with radiotherapy and/or surgery with additional maintenance therapy extending for
6 months to 24 months depending on randomized group for high-risk and very high-risk
groups (according to early results from the ongoing FaR-RMS trial). The timing for
follow-up imaging is summarized in [Supplementary Table S7 ], available online only adapted from the EpSSG, ESPR oncology taskforce and CWS recommendations.[37 ] The IRS-IV trial recommendations by the intergroup Rhabdomyosarcoma Study Group
(IRSG) are widely followed. They recommend neoadjuvant chemotherapy, response assessment
at 10 to 12 weeks, and local treatment with surgery if possible and radiotherapy to
the primary as well as to the metastasis depending on the site.[40 ]
[41 ]
Retinoblastoma
Retinoblastoma is the most prevalent intraocular tumor in children and represents
∼2.5 to 4% of all pediatric cancers.[42 ]
[43 ] According to the National Cancer Registry program, the pooled crude incidence rate
of retinoblastoma in 0 to 14 age group is 3.5 per million and the pooled age standardized
incidence rate is ∼4.4 per million.[44 ] The disease is curable if confined to the globe.
Types, Risk Factors, Etiopathogenesis, and Clinical Presentation
Types, Risk Factors, Etiopathogenesis, and Clinical Presentation
Retinoblastoma clinically presents in two distinct forms:
(1) Bilateral form (25% cases)-Caused by germline mutations of the RB1 gene, localized on chromosome 13q14, and presents as congenital disease or early
in life by 1 year. It could be hereditary or occur de novo.[43 ]
(2) Unilateral form (75% cases)-Random Rb gene mutation is the causative factor for most unilateral forms; however, 10% of
cases are due to germline mutation. The mean age of presentation is ∼2 years.[43 ]
(3) Trilateral retinoblastoma-Bilateral retinoblastoma with an asynchronous intracranial
tumor, usually in the pineal region (pineoblastoma) and rarely in the suprasellar
or parasellar location.
Clinical presentation: The common presentation is leukocoria. Other presentations are squint, nystagmus,
change in visual status or loss of vision, and proptosis in extraocular disease. Advanced
presentations with proptosis and bone marrow and CNS involvement are more commonly
seen in developing countries.
Guidelines for Retinoblastoma Evaluation
Guidelines for Retinoblastoma Evaluation
Diagnosis is established by an ophthalmologist following examination under anesthesia
and intratumoral calcifications detected in the lesion (usually by ultrasound).
Clinical examination:
Ocular examination in the clinic: For visual acuity assessment, anterior segment and
posterior segment examination.
Examination under general anesthesia (EUA): for detailed evaluation including tumor
laterality, number, location, size and vitreous/subretinal seedings. Anterior segment
is also evaluated using a hand held slit lamp. Intraocular pressure is recorded using
a tonometer.
Ultrasound
B-scan is performed using a 7.5 to 10 MHz high-frequency linear probe. Study can be
performed without anesthesia or under sedation. Color Doppler may assist in differentiating
tumor from echogenic effusions and persistent hyperplastic primary vitreous. Ultrasound
is user dependent and this is the major disadvantage in response assessment.
Magnetic Resonance Imaging
Magnetic Resonance Imaging
High-resolution MRI of the orbit and screening of the brain is the examination of
choice for pre-treatment assessment of the tumor ([Table 4 ]). It detects the extent of disease (mainly involvement of the optic nerve and extra-scleral
disease), its size, presence of meningeal spread, or associated intracranial primitive
neuroectodermal tumor (trilateral retinoblastoma).
Table 4
MRI imaging protocol for retinoblastoma
MRI sequence
Plane
Thickness
Sequence coverage
Essential sequences
T2 W FSE/TSE (TE ≥ 120 ms)
Fat-saturated
Axial
≤ 2 mm
Both orbits
T1 W TSE/FSE
Axial
≤ 2 mm
Both orbits
T2W TSE/FSE
Sagittal oblique
≤ 2 mm
Both orbits
T2W fat-saturated/STIR
Coronal
≤ 2 mm
Both orbits
Post contrast (PC)
PC T1W SE FS/nonFS
Axial
≤ 2 mm
Both orbits
PC T1W SE FS/nonFS
Coronal
≤ 2 mm
Both orbits
PC T1W 2D or
(3D GRE ≤ 1 mm)
Axial
≤ 3 mm
Brain
Optional sequences
3D T2W (CISS/SPACE/FIESTA/ DRIVE)
Axial
<1 mm isotropic voxel
Both orbits
PC whole brain T1W 3D MPR
Axial
<1 mm
PC whole Spine T1W
Sagittal
<3 mm
Required if there is optic nerve meningeal sheath involvement
MRI field strength of 3 Tesla with head coil or 1.5 with dedicated orbit/small surface
coil is recommended. Study should be performed under sedation or general anesthesia
(GA) to obtain high-resolution images without eye movements.
To obtain high spatial resolution images, section thickness of ≤ 2 mm and in-plane
pixel size of ≤ 0.5 × 0.5 mm is recommended. The image in axial and sagittal oblique
plane should be aligned with the distal 1 cm end of the optic nerve (just posterior
to the lamina cribrosa).
CT scan: CT is not a preferred modality due to the risk of ionizing radiation especially in
cases with germline mutation. It can be used as an optional modality to detect calcification
if there is diagnostic dilemma or MRI is not available.
Staging: CSF and bone marrow studies should be performed in extraocular disease/ optic nerve
involvement.
Management and Follow-up Imaging (F/U)
Management and Follow-up Imaging (F/U)
Management and F/U imaging is based on staging.[45 ]
Intra-ocular Retinoblastoma Grouping/Staging
Group A: Small tumors (<3 mm) confined to the retina and located at least 3 mm from
foveola and 1.5 mm from optic nerve
Group B: All tumors confined to retina and not in group A; subretinal fluid < 3 mm
from tumor base
Group C: Local vitreous or subretinal seeding (<3 mm from tumor)
Group D: Diffuse vitreous or subretinal seeding (>3 mm from tumor)
Group E: Presence of at least one of the poor prognosis factors (anterior segment/ciliary
body involvement; tumor involving > two-thirds of the globe; iris neo-vascularization;
glaucoma; opaque media from hemorrhage; phthisis bulbi; aseptic orbital cellulitis
due to tumor necrosis)
Treatment Guidelines for Retinoblastoma
For bilateral Rb, systemic therapy along with focal treatment (trans-scleral cryotherapy,
diode laser transpupillary thermotherapy) is the initial treatment. In case of poor
or inadequate response, targeted chemotherapy such as intra-arterial chemotherapy
and/or intravitreal chemotherapy is utilized.
For unilateral intraocular Rb, enucleation is the choice in Group E tumors. Intraarterial
chemotherapy (ophthalmic artery chemo-infusion) is preferred, especially for group
D and select group E eyes. Intravitreal chemotherapy is delivered in persistent vitreous
seeds. Intravenous chemotherapy is administered in Groups C and D and in select Group
E eyes (if buphthalmos is present) where upfront intra-arterial therapy is unavailable.
Patients who have upfront enucleation also receive chemotherapy if histopathological
risk factors are present in the resected specimens.
Extraocular disease is treated with chemotherapy, surgery (enucleation/exenteration)
based on the response and radiotherapy. Patients with bone marrow involvement require
high-dose chemotherapy with stem cell rescue for cure.
Imaging wise, in case of both unilateral and bilateral Rb, an ocular USG, MRI, and
EUA is recommended at baseline.[19 ] Follow-up is done with USG and EUA, and for extra-ocular disease, MRI is also performed.